{"id":"W3088741547","doi":"10.1016/j.annonc.2020.08.2240","title":"LBA12 PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Chugai Pharmaceutical; Samsung; Genentech; Servier; Astellas Pharma; Oncolytics Biotech; Eisai; Genomic Health; Teva Pharmaceutical Industries; Daiichi-Sankyo; PharmaMar; Celgene; G1 Therapeutics; Breast Cancer Research Foundation; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Hazard ratio; Breast cancer; Palbociclib; Internal medicine; Oncology; Adjuvant; Cancer; Interim analysis; Randomized controlled trial; Confidence interval; Metastatic breast cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004229388,0.0004649723,0.00302782,0.0001475181,0.00006010896,0.000007888743,0.0002790265,0.0001321254,0.0006368259],"category_scores_gemma":[0.0001602154,0.0003251821,0.0005641842,0.0003656801,0.0006677156,0.0001518469,0.00004233442,0.0002820532,0.0000029494],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006221413,"about_ca_system_score_gemma":0.000721764,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006166602,"about_ca_topic_score_gemma":0.00008096313,"domain_scores_codex":[0.9969419,0.0002845153,0.00108822,0.0005665711,0.0004581575,0.0006606702],"domain_scores_gemma":[0.9963406,0.001114702,0.0009403337,0.0004347324,0.0008567125,0.0003128824],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7425268,0.001576935,0.00008964704,0.00007058984,0.002214416,0.00005639249,0.001303217,0.0000217941,0.01440294,0.0001258947,0.0003925918,0.2372188],"study_design_scores_gemma":[0.8674712,0.04117996,0.0002013383,0.00009674789,0.0002524738,0.00005957329,0.0002373308,0.00006507799,0.0374859,0.0001479075,0.05253233,0.0002701243],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.940514,0.008926664,0.0009111699,0.04231039,0.0005200837,0.005810366,0.0004231074,0.0001031822,0.0004810365],"genre_scores_gemma":[0.9781279,0.01375881,0.001463278,0.003846942,0.001146983,0.00136061,0.00006351192,0.0001033566,0.0001286343],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2369487,"threshold_uncertainty_score":0.99992,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1106974504715896,"score_gpt":0.4275877126066093,"score_spread":0.3168902621350197,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}